Treatment of cytokine storm syndrome with IL-1 receptor antagonist anakinra in a patient with ARDS caused by COVID-19 infection: A case report

Leonard Kaps; Christian Labenz; Daniel Grimm; Andreas Schwarting; Peter R Galle; Oliver Schreiner

doi:10.1002/ccr3.3307

Treatment of cytokine storm syndrome with IL-1 receptor antagonist anakinra in a patient with ARDS caused by COVID-19 infection: A case report

Clin Case Rep. 2020 Sep 15;8(12):2990-2994. doi: 10.1002/ccr3.3307. eCollection 2020 Dec.

Authors

Leonard Kaps^{1

2}, Christian Labenz¹, Daniel Grimm¹, Andreas Schwarting¹, Peter R Galle¹, Oliver Schreiner¹

Affiliations

¹ Department of Internal Medicine I University Medical Center of the Johannes Gutenberg-University Mainz Germany.
² Institute of Translational Immunology University Medical Center of the Johannes Gutenberg-University Mainz Germany.

Abstract

The biological anakinra appears promising to halt cytokine storm syndrome seen in severe courses of COVID-19. However, immunosuppression with anakinra may facilitate sepsis, necessitating continuous screening for bacterial superinfections.

Publication types

Case Reports